Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 338

1.

DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis.

Kular L, Liu Y, Ruhrmann S, Zheleznyakova G, Marabita F, Gomez-Cabrero D, James T, Ewing E, Lindén M, Górnikiewicz B, Aeinehband S, Stridh P, Link J, Andlauer TFM, Gasperi C, Wiendl H, Zipp F, Gold R, Tackenberg B, Weber F, Hemmer B, Strauch K, Heilmann-Heimbach S, Rawal R, Schminke U, Schmidt CO, Kacprowski T, Franke A, Laudes M, Dilthey AT, Celius EG, Søndergaard HB, Tegnér J, Harbo HF, Oturai AB, Olafsson S, Eggertsson HP, Halldorsson BV, Hjaltason H, Olafsson E, Jonsdottir I, Stefansson K, Olsson T, Piehl F, Ekström TJ, Kockum I, Feinberg AP, Jagodic M.

Nat Commun. 2018 Jun 19;9(1):2397. doi: 10.1038/s41467-018-04732-5.

2.

Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients.

Adriani M, Nytrova P, Mbogning C, Hässler S, Medek K, Jensen PEH, Creeke P, Warnke C, Ingenhoven K, Hemmer B, Sievers C, Lindberg Gasser RL, Fissolo N, Deisenhammer F, Bocskei Z, Mikol V, Fogdell-Hahn A, Kubala Havrdova E, Broët P, Dönnes P, Mauri C, Jury EC; ABIRISK Consortium.

JCI Insight. 2018 Jun 7;3(11). pii: 99274. doi: 10.1172/jci.insight.99274. [Epub ahead of print]

3.

Serum heat shock protein 70 levels as a biomarker for inflammatory processes in multiple sclerosis.

Lechner P, Buck D, Sick L, Hemmer B, Multhoff G.

Mult Scler J Exp Transl Clin. 2018 May 2;4(2):2055217318767192. doi: 10.1177/2055217318767192. eCollection 2018 Apr-Jun.

4.

Association of Retinal Ganglion Cell Layer Thickness With Future Disease Activity in Patients With Clinically Isolated Syndrome.

Zimmermann HG, Knier B, Oberwahrenbrock T, Behrens J, Pfuhl C, Aly L, Kaminski M, Hoshi MM, Specovius S, Giess RM, Scheel M, Mühlau M, Bellmann-Strobl J, Ruprecht K, Hemmer B, Korn T, Paul F, Brandt AU.

JAMA Neurol. 2018 Apr 23. doi: 10.1001/jamaneurol.2018.1011. [Epub ahead of print]

PMID:
29710121
5.

Progressive multifocal leukoencephalopathy after fingolimod treatment.

Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, Merschhemke M.

Neurology. 2018 May 15;90(20):e1815-e1821. doi: 10.1212/WNL.0000000000005529. Epub 2018 Apr 18.

6.

Multiple sclerosis.

Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O.

Lancet. 2018 Apr 21;391(10130):1622-1636. doi: 10.1016/S0140-6736(18)30481-1. Epub 2018 Mar 23. Review.

PMID:
29576504
7.

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F.

Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541. [Epub ahead of print]

PMID:
29532745
8.

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.

Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M, Hartung HP, Jeffery D, Kappos L, Barkhof F, Edan G, Freedman MS, Montalbán X, Müller-Myhsok B, Hemmer B; BEYOND and BENEFIT Study Groups.

Mult Scler. 2018 Mar 1:1352458518763089. doi: 10.1177/1352458518763089. [Epub ahead of print]

PMID:
29521573
9.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

10.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20.

PMID:
29353550
11.

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Erratum in: Eur J Neurol. 2018 Mar;25(3):605.

PMID:
29352526
12.

Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis.

Feucht N, Maier M, Lepennetier G, Pettenkofer M, Wetzlmair C, Daltrozzo T, Scherm P, Zimmer C, Hoshi MM, Hemmer B, Korn T, Knier B.

Mult Scler. 2018 Jan 1:1352458517750009. doi: 10.1177/1352458517750009. [Epub ahead of print]

PMID:
29303033
13.

Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients.

Kalluri SR, Grummel V, Hracsko Z, Pongratz V, Pernpeintner V, Gasperi C, Buck D, Hemmer B; ABIRISK Consortium.

J Autoimmun. 2018 Mar;88:83-90. doi: 10.1016/j.jaut.2017.10.003. Epub 2017 Oct 21.

PMID:
29066027
14.

Cortical pathology in multiple sclerosis detected by the T1/T2-weighted ratio from routine magnetic resonance imaging.

Righart R, Biberacher V, Jonkman LE, Klaver R, Schmidt P, Buck D, Berthele A, Kirschke JS, Zimmer C, Hemmer B, Geurts JJG, Mühlau M.

Ann Neurol. 2017 Oct;82(4):519-529. doi: 10.1002/ana.25020. Epub 2017 Sep 16.

15.

Volume versus surface-based cortical thickness measurements: A comparative study with healthy controls and multiple sclerosis patients.

Righart R, Schmidt P, Dahnke R, Biberacher V, Beer A, Buck D, Hemmer B, Kirschke JS, Zimmer C, Gaser C, Mühlau M.

PLoS One. 2017 Jul 6;12(7):e0179590. doi: 10.1371/journal.pone.0179590. eCollection 2017.

16.

Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.

Amato MP, Derfuss T, Hemmer B, Liblau R, Montalban X, Soelberg Sørensen P, Miller DH; 2016 ECTRIMS Focused Workshop Group.

Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847. [Epub ahead of print]

17.

The spectrum of aseptic central nervous system infections in southern Germany - demographic, clinical and laboratory findings.

Kaminski M, Grummel V, Hoffmann D, Berthele A, Hemmer B.

Eur J Neurol. 2017 Aug;24(8):1062-1070. doi: 10.1111/ene.13335. Epub 2017 Jun 21.

PMID:
28636287
18.

Consensus guidelines for lumbar puncture in patients with neurological diseases.

Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D, Gnanapavan S, Hemmer B, Hoff E, Hort J, Iacobaeus E, Ingelsson M, Jan de Jong F, Jonsson M, Khalil M, Kuhle J, Lleó A, de Mendonça A, Molinuevo JL, Nagels G, Paquet C, Parnetti L, Roks G, Rosa-Neto P, Scheltens P, Skårsgard C, Stomrud E, Tumani H, Visser PJ, Wallin A, Winblad B, Zetterberg H, Duits F, Teunissen CE.

Alzheimers Dement (Amst). 2017 May 18;8:111-126. doi: 10.1016/j.dadm.2017.04.007. eCollection 2017.

19.

CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder.

Kowarik MC, Astling D, Gasperi C, Wemlinger S, Schumann H, Dzieciatkowska M, Ritchie AM, Hemmer B, Owens GP, Bennett JL.

Ann Clin Transl Neurol. 2017 May 9;4(6):369-380. doi: 10.1002/acn3.418. eCollection 2017 Jun.

20.

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.

Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I; NEMOS (Neuromyelitis Optica Study Group).

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639-647. doi: 10.1136/jnnp-2017-315603. Epub 2017 Jun 1.

21.

Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters.

Biberacher V, Schmidt P, Selter RC, Pernpeinter V, Kowarik MC, Knier B, Buck D, Hoshi MM, Korn T, Berthele A, Kirschke JS, Zimmer C, Hemmer B, Mühlau M.

Mult Scler. 2018 Jul;24(8):1115-1125. doi: 10.1177/1352458517712078. Epub 2017 May 25.

PMID:
28539075
22.

Association of Retinal Architecture, Intrathecal Immunity, and Clinical Course in Multiple Sclerosis.

Knier B, Leppenetier G, Wetzlmair C, Aly L, Hoshi MM, Pernpeintner V, Biberacher V, Berthele A, Mühlau M, Zimmer C, Hemmer B, Korn T.

JAMA Neurol. 2017 Jul 1;74(7):847-856. doi: 10.1001/jamaneurol.2017.0377.

23.

Corrigendum: Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells.

Heink S, Yogev N, Garbers C, Herwerth M, Aly L, Gasperi C, Husterer V, Croxford AL, Möller-Hackbarth K, Bartsch HS, Sotlar K, Krebs S, Regen T, Blum H, Hemmer B, Misgeld T, Wunderlich TF, Hidalgo J, Oukka M, Rose-John S, Schmidt-Supprian M, Waisman A, Korn T.

Nat Immunol. 2017 Mar 22;18(4):474. doi: 10.1038/ni0417-474b. No abstract available.

PMID:
28323263
24.

Daclizumab for the treatment of relapsing-remitting multiple sclerosis.

Herwerth M, Hemmer B.

Expert Opin Biol Ther. 2017 Jun;17(6):747-753. doi: 10.1080/14712598.2017.1304913. Epub 2017 Apr 7.

PMID:
28286970
25.

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.

Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, Donnellan N, Comabella M, Montalban X, Kieseier B, Soelberg Sørensen P, Hartung HP, Derfuss T, Lawton A, Sikkema D, Pallardy M, Hemmer B, Deisenhammer F, Broët P, Dönnes P, Davidson J, Fogdell-Hahn A; ABIRISK Consortium.

PLoS One. 2017 Feb 7;12(2):e0170395. doi: 10.1371/journal.pone.0170395. eCollection 2017.

26.

Multiple sclerosis in 2016: Immune-directed therapies in MS - efficacy and limitations.

Hemmer B, Mühlau M.

Nat Rev Neurol. 2017 Feb;13(2):72-74. doi: 10.1038/nrneurol.2017.2. Epub 2017 Jan 20. No abstract available.

PMID:
28106067
27.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

28.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

29.

From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.

Aly L, Hemmer B, Korn T.

Curr Neuropharmacol. 2017;15(6):874-891. doi: 10.2174/1570159X14666161208151525. Review.

30.

Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells.

Heink S, Yogev N, Garbers C, Herwerth M, Aly L, Gasperi C, Husterer V, Croxford AL, Möller-Hackbarth K, Bartsch HS, Sotlar K, Krebs S, Regen T, Blum H, Hemmer B, Misgeld T, Wunderlich TF, Hidalgo J, Oukka M, Rose-John S, Schmidt-Supprian M, Waisman A, Korn T.

Nat Immunol. 2017 Jan;18(1):74-85. doi: 10.1038/ni.3632. Epub 2016 Nov 28. Erratum in: Nat Immunol. 2017 Mar 22;18(4):474.

31.

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.

Bachelet D, Hässler S, Mbogning C, Link J, Ryner M, Ramanujam R, Auer M, Hyldgaard Jensen PE, Koch-Henriksen N, Warnke C, Ingenhoven K, Buck D, Grummel V, Lawton A, Donnellan N, Hincelin-Mery A, Sikkema D, Pallardy M, Kieseier B, Hemmer B, Hartung HP, Soelberg Sorensen P, Deisenhammer F, Dönnes P, Davidson J, Fogdell-Hahn A, Broët P; ABIRISK Consortium.

PLoS One. 2016 Nov 2;11(11):e0162752. doi: 10.1371/journal.pone.0162752. eCollection 2016.

32.

HLA Genetic Risk Burden in Multiple Sclerosis.

Mühlau M, Andlauer TF, Hemmer B.

JAMA Neurol. 2016 Dec 1;73(12):1500-1501. doi: 10.1001/jamaneurol.2016.4329. No abstract available.

PMID:
27775759
33.

Influence of female sex and fertile age on neuromyelitis optica spectrum disorders.

Borisow N, Kleiter I, Gahlen A, Fischer K, Wernecke KD, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Weissert R, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Rückriem L, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Hellwig K; NEMOS (Neuromyelitis Optica Study Group).

Mult Scler. 2017 Jul;23(8):1092-1103. doi: 10.1177/1352458516671203. Epub 2016 Oct 6.

PMID:
27758954
34.

Spatially explicit assessment of estuarine fish after Deepwater Horizon oil spill: trade-off in complexity and parsimony.

Awkerman JA, Hemmer B, Almario A, Lilavois C, Barron MG, Raimondo S.

Ecol Appl. 2016 Sep;26(6):1708-1720. doi: 10.1890/15-1410.1.

PMID:
27755711
35.

Effects of Louisiana crude oil on the sheepshead minnow (Cyprinodon variegatus) during a life-cycle exposure to laboratory oiled sediment.

Raimondo S, Hemmer BL, Lilavois CR, Krzykwa J, Almario A, Awkerman JA, Barron MG.

Environ Toxicol. 2016 Nov;31(11):1627-1639. doi: 10.1002/tox.22167. Epub 2015 Jun 30.

PMID:
26129909
36.

Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis.

Knier B, Schmidt P, Aly L, Buck D, Berthele A, Mühlau M, Zimmer C, Hemmer B, Korn T.

Brain. 2016 Nov 1;139(11):2855-2863. doi: 10.1093/brain/aww219. No abstract available.

PMID:
27581073
37.

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.

Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.

38.

Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barré syndrome.

Schirmer L, Worthington V, Solloch U, Loleit V, Grummel V, Lakdawala N, Grant D, Wassmuth R, Schmidt AH, Gebhardt F, Andlauer TF, Sauter J, Berthele A, Lunn MP, Hemmer B.

J Neurol. 2016 Oct;263(10):2105-13. doi: 10.1007/s00415-016-8237-6. Epub 2016 Aug 2.

PMID:
27485170
39.

Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis.

Biberacher V, Schmidt P, Keshavan A, Boucard CC, Righart R, Sämann P, Preibisch C, Fröbel D, Aly L, Hemmer B, Zimmer C, Henry RG, Mühlau M.

Neuroimage. 2016 Nov 15;142:188-197. doi: 10.1016/j.neuroimage.2016.07.035. Epub 2016 Jul 16.

PMID:
27431758
40.

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.

Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F, Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B.

Sci Adv. 2016 Jun 17;2(6):e1501678. doi: 10.1126/sciadv.1501678. eCollection 2016 Jun.

41.

The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion.

Hucke S, Herold M, Liebmann M, Freise N, Lindner M, Fleck AK, Zenker S, Thiebes S, Fernandez-Orth J, Buck D, Luessi F, Meuth SG, Zipp F, Hemmer B, Engel DR, Roth J, Kuhlmann T, Wiendl H, Klotz L.

Acta Neuropathol. 2016 Sep;132(3):413-31. doi: 10.1007/s00401-016-1593-6. Epub 2016 Jul 6.

PMID:
27383204
42.

Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.

Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P, Montalban X, Ziemssen T, Hunter B, Arnould S, Wallström E, Selmaj K.

JAMA Neurol. 2016 Sep 1;73(9):1089-98. doi: 10.1001/jamaneurol.2016.1451.

PMID:
27380540
43.

PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?

Lehmann-Horn K, Penkert H, Grein P, Leppmeier U, Teuber-Hanselmann S, Hemmer B, Berthele A.

Neurology. 2016 Jul 26;87(4):440-1. doi: 10.1212/WNL.0000000000002900. Epub 2016 Jun 24. No abstract available.

PMID:
27343070
44.

Spontaneous Cerebrospinal Fluid Leak With Venous Engorgement Mimicking a Contrast-Enhancing Cervical Mass.

Herwerth M, Prothmann S, Kreiser K, Hemmer B, Ploner M.

JAMA Neurol. 2016 Jul 1;73(7):886-7. doi: 10.1001/jamaneurol.2016.0277. No abstract available.

PMID:
27243137
45.

Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1- and T2-weighted MR image intensity.

Beer A, Biberacher V, Schmidt P, Righart R, Buck D, Berthele A, Kirschke J, Zimmer C, Hemmer B, Mühlau M.

J Neurol. 2016 Aug;263(8):1495-502. doi: 10.1007/s00415-016-8156-6. Epub 2016 May 13.

PMID:
27178000
46.

Power estimation for non-standardized multisite studies.

Keshavan A, Paul F, Beyer MK, Zhu AH, Papinutto N, Shinohara RT, Stern W, Amann M, Bakshi R, Bischof A, Carriero A, Comabella M, Crane JC, D'Alfonso S, Demaerel P, Dubois B, Filippi M, Fleischer V, Fontaine B, Gaetano L, Goris A, Graetz C, Gröger A, Groppa S, Hafler DA, Harbo HF, Hemmer B, Jordan K, Kappos L, Kirkish G, Llufriu S, Magon S, Martinelli-Boneschi F, McCauley JL, Montalban X, Mühlau M, Pelletier D, Pattany PM, Pericak-Vance M, Cournu-Rebeix I, Rocca MA, Rovira A, Schlaeger R, Saiz A, Sprenger T, Stecco A, Uitdehaag BMJ, Villoslada P, Wattjes MP, Weiner H, Wuerfel J, Zimmer C, Zipp F; International Multiple Sclerosis Genetics Consortium. Electronic address: AIVINSON@PARTNERS.ORG, Hauser SL, Oksenberg JR, Henry RG.

Neuroimage. 2016 Jul 1;134:281-294. doi: 10.1016/j.neuroimage.2016.03.051. Epub 2016 Apr 1.

47.

In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology.

Herwerth M, Kalluri SR, Srivastava R, Kleele T, Kenet S, Illes Z, Merkler D, Bennett JL, Misgeld T, Hemmer B.

Ann Neurol. 2016 Mar 6. doi: 10.1002/ana.24630. [Epub ahead of print]

48.

[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, Meier U, Meuth SG, Paul F, Salmen A, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber MS, Ziemssen T, Zipp F, Wiendl H.

Nervenarzt. 2016 Jun;87(6):645-59. doi: 10.1007/s00115-016-0077-1. Review. German.

PMID:
26927677
49.

Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab.

Kowarik MC, Hoshi M, Hemmer B, Berthele A.

Neurol Neuroimmunol Neuroinflamm. 2016 Feb 10;3(2):e208. doi: 10.1212/NXI.0000000000000208. eCollection 2016 Apr. No abstract available.

50.

B cell-directed therapies in multiple sclerosis.

Gasperi C, Stüve O, Hemmer B.

Neurodegener Dis Manag. 2016;6(1):37-47. doi: 10.2217/nmt.15.67. Review.

PMID:
26782316

Supplemental Content

Loading ...
Support Center